{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T06:11:49Z","timestamp":1788588709169,"version":"build-2803163510"},"reference-count":52,"publisher":"Kurume Medical Journal","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Kurume Med. J."],"published-print":{"date-parts":[[2026]]},"DOI":"10.2739\/kurumemedj.ms7312004","type":"journal-article","created":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T22:11:24Z","timestamp":1787263884000},"source":"Crossref","is-referenced-by-count":0,"title":["TL1A\u2013DR3 Signaling in Inflammatory Bowel Disease: From Pathogenesis to Therapeutic Targeting"],"prefix":"10.2739","author":[{"given":"KOZO","family":"TSURUTA","sequence":"first","affiliation":[{"name":"Division of Gastroenterology, Department of Medicine, Kurume University School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"SHINICHIRO","family":"YOSHIOKA","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology, Department of Medicine, Kurume University School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"HIDETOSHI","family":"TAKEDATSU","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology, Department of Medicine, Kurume University School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1445","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Fudman DI, McConnell RA, Ha C, and Singh S. Modern Advanced Therapies for Inflammatory Bowel Diseases: Practical Considerations and Positioning. Clin Gastroenterol Hepatol 2025; 23:454-468.","DOI":"10.1016\/j.cgh.2024.06.050"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. D\u2019Alessio S, Ungaro F, Noviello D, and Lovisa S. Revisiting fibrosis in inflammatory bowel disease: the gut thickens. Nat Rev Gastroenterol Hepatol 2022; 19:169-184.","DOI":"10.1038\/s41575-021-00543-0"},{"key":"3","doi-asserted-by":"publisher","unstructured":"3. Migone TS, Zhang J, Luo X, Zhuang L, Chen C et al. TL1A is a TNF-like ligand for DR3 and TR6\/DcR3 and functions as a T cell costimulator. Immunity 2002; 16:479-492.","DOI":"10.1016\/S1074-7613(02)00283-2"},{"key":"4","doi-asserted-by":"publisher","unstructured":"4. Tan KB, Harrop J, Reddy M, et al. Characterization of a novel TNF-like ligand and recently described TNF ligand and TNF receptor superfamily genes and their constitutive and inducible expression in hematopoietic and non-hematopoietic cells. Gene 1997; 204:35-46.","DOI":"10.1016\/S0378-1119(97)00509-X"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Kitson J, Raven T, Jiang YP, Goeddel DV, Giles KM et al. A death-domain-containing receptor that mediates apoptosis. Nature 1996; 384:372-375.","DOI":"10.1038\/384372a0"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Screaton GR, Xu XN, Olsen AL, Cowper AE, Tan R et al. LARD: a new lymphoid-specific death domain containing receptor regulated by alternative pre-mRNA splicing. Proc Natl Acad Sci U S A 1997; 94:4615-4619.","DOI":"10.1073\/pnas.94.9.4615"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Fang L, Adkins B, Deyev V, and Podack ER. Essential role of TNF receptor superfamily 25 (TNFRSF25) in the development of allergic lung inflammation. J Exp Med 2008; 205:1037-1048.","DOI":"10.1084\/jem.20072528"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Cavallini C, Lovato O, Bertolaso A, Pacelli L, Zoratti E et al. The TNF-family cytokine TL1A inhibits proliferation of human activated B cells. PLoS One 2013; 8:e60136.","DOI":"10.1371\/journal.pone.0060136"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Wang X, Hu Y, Charpentier T, Lamarre A, Qi S et al. TNF-like ligand 1A (TL1A) gene knockout leads to ameliorated collagen-induced arthritis in mice: implication of TL1A in humoral immune responses. J Immunol 2013; 191:5420-5429.","DOI":"10.4049\/jimmunol.1301475"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Valatas V, Kolios G, and Bamias G. TL1A (TNFSF15) and DR3 (TNFRSF25): A Co-stimulatory System of Cytokines With Diverse Functions in Gut Mucosal Immunity. Front Immunol 2019; 10:583.","DOI":"10.3389\/fimmu.2019.00583"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Bamias G, Menghini P, Pizarro TT, Cominelli F et al. Targeting TL1A and DR3: the new frontier of anti-cytokine therapy in IBD. Gut 2025; 74:652-668.","DOI":"10.1136\/gutjnl-2024-332504"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Cordero RY, Cordero JB, Stiemke AB, Datta LW, Buyske S et al. Trans-ancestry, Bayesian meta-analysis discovers 20 novel risk loci for inflammatory bowel disease in an African American, East Asian and European cohort. Hum Mol Genet 2023; 32:873-882.","DOI":"10.1093\/hmg\/ddac269"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Yamazaki K, McGovern D, Ragoussis J, Paolucci M, Butler H et al. Single nucleotide polymorphisms in TNFSF15 confer susceptibility to Crohn\u2019s disease. Hum Mol Genet 2005; 14:3499-3506.","DOI":"10.1093\/hmg\/ddi379"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Yang DH, Yang SK, Song K, Hong M, Park SH et al. TNFSF15 is an independent predictor for the development of Crohn\u2019s disease-related complications in Koreans. J Crohns Colitis 2014; 8:1315-1326.","DOI":"10.1016\/j.crohns.2014.04.002"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Zhan C, Yan Q, Patskovsky Y, Li Z, Toro R et al. Biochemical and structural characterization of the human TL1A ectodomain. Biochemistry 2009; 48:7636-7645.","DOI":"10.1021\/bi900031w"},{"key":"16","doi-asserted-by":"publisher","unstructured":"16. Chinnaiyan AM, O\u2019Rourke K, Yu GL, Lyons RH, Garg M et al. Signal transduction by DR3, a death domain-containing receptor related to TNFR-1 and CD95. Science 1996; 274:990-992.","DOI":"10.1126\/science.274.5289.990"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Zhang J, Zhang D, Pan Y, Liu X, Xu J et al. The TL1A-DR3 Axis in Asthma: Membrane-Bound and Secreted TL1A Co-Determined the Development of Airway Remodeling. Allergy Asthma Immunol Res 2022; 14:233-253.","DOI":"10.4168\/aair.2022.14.2.233"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Xu WD, Li R, and Huang AF. Role of TL1A in Inflammatory Autoimmune Diseases: A Comprehensive Review. Front Immunol 2022; 13:891328.","DOI":"10.3389\/fimmu.2022.891328"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Bamias G, Martin C, 3rd, Marini M, Hoang S, Mishina M et al. Expression, localization, and functional activity of TL1A, a novel Th1-polarizing cytokine in inflammatory bowel disease. J Immunol 2003; 171:4868-4874.","DOI":"10.4049\/jimmunol.171.9.4868"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Prehn JL, Mehdizadeh S, Landers CJ, Luo X, Cha SC et al. Potential role for TL1A, the new TNF-family member and potent costimulator of IFN-gamma, in mucosal inflammation. Clin Immunol 2004; 112:66-77.","DOI":"10.1016\/j.clim.2004.02.007"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Pai YC, Weng LT, Wei SC, Wu LL, Shih DQ et al. Gut microbial transcytosis induced by tumor necrosis factor-like 1A-dependent activation of a myosin light chain kinase splice variant contributes to IBD. J Crohns Colitis 2021; 15:258-72.","DOI":"10.1093\/ecco-jcc\/jjaa165"},{"key":"22","doi-asserted-by":"publisher","unstructured":"22. Takedatsu H, Michelsen KS, Wei B, Landers CJ, Thomas LS et al. TL1A (TNFSF15) regulates the development of chronic colitis by modulating both T-helper 1 and T-helper 17 activation. Gastroenterology 2008; 135:552-67.","DOI":"10.1053\/j.gastro.2008.04.037"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23. Meylan F, Davidson TS, Kahle E, Kinder M, Acharya K et al. The TNF-family receptor DR3 is essential for diverse T cell-mediated inflammatory diseases. Immunity 2008; 29:79-89.","DOI":"10.1016\/j.immuni.2008.04.021"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24. Kamada N, Hisamatsu T, Honda H, Kobayashi T, Chinen H et al. TL1A produced by lamina propria macrophages induces Th1 and Th17 immune responses in cooperation with IL-23 in patients with Crohn\u2019s disease. Inflamm Bowel Dis 2010; 16:568-75.","DOI":"10.1002\/ibd.21124"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25. Pappu BP, Borodovsky A, Zheng TS, Yang X, Wu P et al. TL1A-DR3 interaction regulates Th17 cell function and Th17-mediated autoimmune disease. J Exp Med 2008; 205:1049-1062.","DOI":"10.1084\/jem.20071364"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26. Meylan F, Hawley ET, Barron L, Barlow JL, Penumetcha P et al. The TNF-family cytokine TL1A promotes allergic immunopathology through group 2 innate lymphoid cells. Mucosal Immunol 2014; 7:958-968.","DOI":"10.1038\/mi.2013.114"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27. Yu X, Pappu R, Ramirez-Carrozzi V, Ota N, Caplazi P et al. TNF superfamily member TL1A elicits type 2 innate lymphoid cells at mucosal barriers. Mucosal Immunol 2014; 7:730-740.","DOI":"10.1038\/mi.2013.92"},{"key":"28","doi-asserted-by":"publisher","unstructured":"28. Wang S, Xia P, Chen Y, Qu Y, Xiong Z et al. Regulatory Innate Lymphoid Cells Control Innate Intestinal Inflammation. Cell 2017; 171:201-216.e18.","DOI":"10.1016\/j.cell.2017.07.027"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29. Zeng B, Shi S, Liu J, and Xing F. Commentary: Regulatory Innate Lymphoid Cells Control Innate Intestinal Inflammation. Front Immunol 2018; 9:1522.","DOI":"10.3389\/fimmu.2018.01522"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30. Meylan F, Song YJ, Fuss I, Villarreal S, Kahle E et al. The TNF-family cytokine TL1A drives IL-13-dependent small intestinal inflammation. Mucosal Immunol 2010; 4:172-185.","DOI":"10.1038\/mi.2010.67"},{"key":"31","doi-asserted-by":"crossref","unstructured":"31. Castellanos JG, Woo V, Viladomiu M, Putzel G, Lima S et al. Microbiota-Induced TNF-like Ligand 1A Drives Group 3 Innate Lymphoid Cell-Mediated Barrier Protection and Intestinal T Cell Activation during Colitis. Immunity 2018; 49:1077-1089.e5.","DOI":"10.1016\/j.immuni.2018.10.014"},{"key":"32","doi-asserted-by":"crossref","unstructured":"32. Shimodaira Y, More SK, Hamade H, Blackwood AY, Abraham JP et al. DR3 Regulates Intestinal Epithelial Homeostasis and Regeneration After Intestinal Barrier Injury. Cell Mol Gastroenterol Hepatol 2023; 16:83-105.","DOI":"10.1016\/j.jcmgh.2023.03.008"},{"key":"33","doi-asserted-by":"publisher","unstructured":"33. Rieder F, Mukherjee PK, Massey WJ, Wang Y, and Fiocchi C. Fibrosis in IBD: from pathogenesis to therapeutic targets. Gut 2024; 73:854-866.","DOI":"10.1136\/gutjnl-2023-329963"},{"key":"34","doi-asserted-by":"crossref","unstructured":"34. Shih DQ, Barrett R, Zhang X, Yeager N, Koon HW et al. Constitutive TL1A (TNFSF15) expression on lymphoid or myeloid cells leads to mild intestinal inflammation and fibrosis. PLoS One 2011; 6:e16090.","DOI":"10.1371\/journal.pone.0016090"},{"key":"35","doi-asserted-by":"crossref","unstructured":"35. Shih DQ, Zheng L, Zhang X, Zhang H, Kanazawa Y et al. Inhibition of a novel fibrogenic factor Tl1a reverses established colonic fibrosis. Mucosal Immunol 2014; 7:1492-1503.","DOI":"10.1038\/mi.2014.37"},{"key":"36","doi-asserted-by":"crossref","unstructured":"36. Jacob N, Jacobs JP, Kumagai K, et al. Inflammation-independent TL1A-mediated intestinal fibrosis is dependent on the gut microbiome. Mucosal Immunol 2018; 11:1466-1476.","DOI":"10.1038\/s41385-018-0055-y"},{"key":"37","doi-asserted-by":"crossref","unstructured":"37. Jacob N, Kumagai K, Abraham JP, Shimodaira Y, Ye Y et al. Direct signaling of TL1A-DR3 on fibroblasts induces intestinal fibrosis in vivo. Sci Rep 2020; 10:18189.","DOI":"10.1038\/s41598-020-75168-5"},{"key":"38","doi-asserted-by":"crossref","unstructured":"38. Steele H, Sachen K, McKnight AJ, Soloff R, and Herro R. Targeting TL1A\/DR3 Signaling Offers a Therapeutic Advantage to Neutralizing IL13\/IL4R\u03b1 in Muco-Secretory Fibrotic Disorders. Front Immunol 2021; 12:602127.","DOI":"10.3389\/fimmu.2021.692127"},{"key":"39","doi-asserted-by":"crossref","unstructured":"39. Zhang J, Zhang J, Wu D, Wang J, and Dong W. Associations between TNFSF15 polymorphisms and susceptibility to ulcerative colitis and Crohn\u2019s disease: A meta-analysis. Autoimmunity 2014; 47:512-518.","DOI":"10.3109\/08916934.2014.930735"},{"key":"40","doi-asserted-by":"crossref","unstructured":"40. Michelsen KS, Thomas LS, Taylor KD, Yu QT, Mei L et al. IBD-associated TL1A gene (TNFSF15) haplotypes determine increased expression of TL1A protein. PLoS One 2009; 4:e4719.","DOI":"10.1371\/journal.pone.0004719"},{"key":"41","doi-asserted-by":"crossref","unstructured":"41. Kakuta Y, Ueki N, Kinouchi Y, Negoro K, Endo K et al. TNFSF15 transcripts from risk haplotype for Crohn\u2019s disease are overexpressed in stimulated T cells. Hum Mol Genet 2009; 18:1089-1098.","DOI":"10.1093\/hmg\/ddp005"},{"key":"42","doi-asserted-by":"crossref","unstructured":"42. Hedl M and Abraham C. A TNFSF15 disease-risk polymorphism increases pattern-recognition receptor-induced signaling through caspase-8-induced IL-1. Proc Natl Acad Sci USA 2014; 111:13451-6.","DOI":"10.1073\/pnas.1404178111"},{"key":"43","doi-asserted-by":"crossref","unstructured":"43. Sun R, Hedl M, and Abraham C. TNFSF15 Promotes Antimicrobial Pathways in Human Macrophages and These Are Modulated by TNFSF15 Disease-Risk Variants. Cell Mol Gastroenterol Hepatol 2021; 11:249-272.","DOI":"10.1016\/j.jcmgh.2020.08.003"},{"key":"44","doi-asserted-by":"crossref","unstructured":"44. Nakagome S, Chinen H, Iraha A, Hokama A, Takeyama Y et al. Confounding effects of microbiome on the susceptibility of TNFSF15 to Crohn\u2019s disease in the Ryukyu Islands. Hum Genet 2017; 136:387-397.","DOI":"10.1007\/s00439-017-1764-0"},{"key":"45","doi-asserted-by":"crossref","unstructured":"45. Hu S, Vich Vila A, Gacesa R, Collij V, Stevens C et al. Whole exome sequencing analyses reveal gene-microbiota interactions in the context of IBD. Gut 2021; 70:285-296.","DOI":"10.1136\/gutjnl-2019-319706"},{"key":"46","doi-asserted-by":"crossref","unstructured":"46. Banfield C, Rudin D, Bhattacharya I, Goteti K, Li G et al. First-in-human, randomized dose-escalation study of the safety, tolerability, pharmacokinetics, pharmacodynamics and immunogenicity of PF-06480605 in healthy subjects. Br J Clin Pharmacol 2020; 86:812-824.","DOI":"10.1111\/bcp.14187"},{"key":"47","doi-asserted-by":"crossref","unstructured":"47. Danese S, Klopocka M, Scherl EJ, Romatowski J, Allegretti JR et al. Anti-TL1A Antibody PF-06480605 Safety and Efficacy for Ulcerative Colitis: A Phase 2a Single-Arm Study. Clin Gastroenterol Hepatol 2021; 19:2324-2332.e6.","DOI":"10.1016\/j.cgh.2021.06.011"},{"key":"48","doi-asserted-by":"crossref","unstructured":"48. Sands BE, Feagan BG, Peyrin-Biroulet L, Danese S, Rubin D et al. Phase 2 Trial of Anti-TL1A Monoclonal Antibody Tulisokibart for Ulcerative Colitis. N Engl J Med 2024; 391:1119-1129.","DOI":"10.1056\/NEJMoa2314076"},{"key":"49","doi-asserted-by":"crossref","unstructured":"49. Feagan BG, Sands BE, Siegel CA, Dubinsky MC, Longman RS et al. Safety and efficacy of the anti-TL1A monoclonal antibody tulisokibart for Crohn\u2019s disease: a phase 2a induction trial. Lancet Gastroenterol Hepatol 2025; 10:715-725.","DOI":"10.1016\/S2468-1253(25)00071-8"},{"key":"50","doi-asserted-by":"crossref","unstructured":"50. Reinisch W, Stoyanov S, Raphael G, and Barkay H. P998 Phase 2 basket design study evaluating the efficacy and safety of an anti-TL1A antibody (TEV-48574) in moderate to severe ulcerative colitis or Crohn\u2019s Disease (RELIEVE UCCD). Journal of Crohn\u2019s and Colitis 2024; 18: i1802.","DOI":"10.1093\/ecco-jcc\/jjad212.1128"},{"key":"51","doi-asserted-by":"crossref","unstructured":"51. Honap S, Sands BE, Jairath V, Danese S, Vicaut E et al. Basket, Umbrella, and Platform Trials: The Potential for Master Protocol-Based Trials in Inflammatory Bowel Disease. Gastroenterology 2024; 167:636-642.e2.","DOI":"10.1053\/j.gastro.2024.04.020"},{"key":"52","doi-asserted-by":"crossref","unstructured":"52. Ma C, Solitano V, Danese S, and Jairath V. The Future of Clinical Trials in Inflammatory Bowel Disease. Clin Gastroenterol Hepatol 2025; 23:480-489.","DOI":"10.1016\/j.cgh.2024.06.036"}],"container-title":["The Kurume Medical Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/kurumemedj\/advpub\/0\/advpub_MS7312004\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T05:27:11Z","timestamp":1788586031000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/kurumemedj\/advpub\/0\/advpub_MS7312004\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026]]},"references-count":52,"URL":"https:\/\/doi.org\/10.2739\/kurumemedj.ms7312004","relation":{},"ISSN":["0023-5679","1881-2090"],"issn-type":[{"value":"0023-5679","type":"print"},{"value":"1881-2090","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026]]},"article-number":"MS7312004"}}